{"id":"NCT02576847","sponsor":"Maruho Co., Ltd.","briefTitle":"Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel","officialTitle":"A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10","primaryCompletion":"2017-07-14","completion":"2018-02-08","firstPosted":"2015-10-15","resultsPosted":"2022-07-06","lastUpdate":"2022-07-19"},"enrollment":307,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rosacea"],"interventions":[{"type":"DRUG","name":"Omiganan","otherNames":[]}],"arms":[{"label":"Treatment","type":"EXPERIMENTAL"}],"summary":"This study evaluates the long-term safety of once-daily application of Omiganan topical gel in subjects with severe papulopustular rosacea.","primaryOutcome":{"measure":"Number of Subjects With 1 or More Treatment-related Treatment-Emergent Adverse Events","timeFrame":"Up to 12 months","effectByArm":[{"arm":"Treatment","deltaMin":48,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":28,"countries":["United States","Australia","Canada","France","Netherlands","New Zealand","Sweden","United Kingdom"]},"refs":{"pmids":["36781451"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":307},"commonTop":["Rosacea","Headache","Viral upper respiratory tract infection","Application site pain","Upper respiratory tract infection"]}}